ArticleThe oncologist2021

FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?

Irene S Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.